CDX2− carcinomas were associated with reduced 3‐year (60 per cent versus 77·8 per cent for CDX+ tumours; P = 0·018) and 5‐year (51·0 versus 70·1 per cent respectively; P = 0·009) overall survival (Fig. 1b). This evidence concerns the gene CDX2 and carcinoma.